Brief: Rhovac's Prostate Cancer Drug Candidate Is Granted Fast Track Designation By The FDA

Chosa Oncology AB

25/11/2020 07:23

Nov 25 (Reuters) - RhoVac AB  RHOVAC.TE :
    * RHOVAC'S PROSTATE CANCER DRUG CANDIDATE, RV001, IS GRANTED FAST TRACK DESIGNATION BY THE
FDA
    * RHOVAC'S PROSTATE CANCER DRUG CANDIDATE, RV001, IS GRANTED FAST TRACK DESIGNATION BY THE
FDA
    * RHOVAC AB - DRUG CANDIDATE IS CURRENTLY ENGAGED IN A PHASE IIB CLINICAL TRIAL IN PROSTATE
CANCER
    * RHOVAC AB - STUDY AIMS TO CONCLUDE IN BEGINNING OF 2022

Source text for Eikon:  ID:nWkr9f30JD 
Further company coverage:  RHOVAC.TE 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))